Press Release

Rising Personalized Treatment Demand Drive Intratumoral Cancer Therapy Market

The Global Intratumoral Cancer Therapy market is projected to grow at a CAGR of around 11.1% during the forecast period of 2023-28, cites MarkNtel Advisors in the recent research report. The rising prevalence of cancer & the soaring demand for targeted & personalized medicine for cancer treatment is driving the market. With the surging advancement in technology for the development of cancer medication, the evolution of more precise & effective cancer therapies has been observed in the market.

Furthermore, as the number of cancer patients rises globally, the requirement for this therapy is also seen among the patients due to the increasing awareness of the adverse effects of other cancer therapies, such as chemotherapy & radiation therapy, after the treatment. This results in the gradual shift of the adoption of Intratumoral cancer therapy in the coming years as well.

Furthermore, rising consumer awareness of personalized medicine for better efficacy over traditional therapy is projected to increase demand for this therapy in the forecast years, as it necessitates the study of individuals' genetic profiles for the treatment, which improves the efficiency of the therapy. Also, growing awareness of the genetic & molecular basis of diseases for personalized medicine would promote the development of personalized cancer medicines in the market.

Additionally, Intratumoral drug delivery is a rapidly emerging sector of R&D, with various biotechnology companies investing in the evolution of innovative drug delivery systems. As companies are launching new & effective technologies for cancer treatment in the market, the adoption of this therapy is gradually witnessing an upward trend. Additionally, numerous mergers & acquisitions are taking place to broaden, diversify, and improve their product portfolio in cancer therapy.

Moreover, biotechnology companies, like OncoSec Medical Incorporated and Intensity Therapeutics, are working to come up with effective therapies to treat several cancer diseases like prostrate, breast, etc., which are mostly in the final phases & needs instant & more adequate treatment. This has also increased the market revenue of the biopharmaceutical company & would create a potential growth opportunity for the market in the near future., further states the research report, “Global Intratumoral Cancer Therapy Market Analysis, 2023.”

Monoclonal Antibody Gaining Popularity in the Targeted Cancer Therapy

Based on the type, the market is further bifurcated into Monoclonal Antibodies (mAbs), Pathogen-associated Molecular Patterns (PAMPs), Viruses, Plasmids, Cell & Gene Therapies, Small Molecules, and Cytokines. Among all, Monoclonal antibodies (mAbs) are gaining popularity in cancer treatment therapy due to their ability to target cancer cells with high specificity, potentially reducing off-target effects & enhancing efficacy. Moreover, the ability to administrate the monoclonal antibody directly into the tumor makes it an optimum choice for the therapy, which results in the high efficiency of Intratumoral cancer therapy, hence, driving the demand for this therapy in the market.

North America to Capture Potential Market Share

Geographically, North America is predicted to hold a significant market share due to the rising prevalence of cancer cases in the country, which requires new & effective therapies to treat cancer patients. The presence of various biotechnology firms' R&D laboratories & investment in the widespread use of technology among patients would drive the demand for this therapy in the forecast years. Hence, the investments from the government & biotechnology companies to diversify the research of Intratumoral cancer therapy for cancer treatment would drive the market in the forecast year.

Competitive Landscape

With strategic initiatives, such as mergers, collaborations, and acquisitions, the leading market players, including Amgen INc., Sirnaomics, Checkmate Pharmaceuticals, Immunovative Therapies, Idera Pharmaceuticals, Daiichi Sankyo, Philogen, Apexigen, Merck, OncoSec Medical Incorporated, DNAtrix, Istari oncology, Nanobiotix, Exicure are looking forward to strengthening their market position.

Key Questions Answered in the Research Report

1. What are the industry’s overall statistics or estimates (Overview, Size- By Value, Forecast Numbers, Segmentation, Shares)?
2. What are the trends influencing the current scenario of the market?
3. What key factors would propel and impede the industry across the region?
4. How has the industry been evolving in terms of geography & product adoption?
5. How has the competition been shaping across various countries?
6. How has the buying behavior, customer inclination, and expectations from product manufacturers been evolving during 2018-28?
7. Who are the key competitors, and what strategic partnerships or ventures are they coming up with to stay afloat during the projected time frame?